Latest News and Press Releases

Blinded safety data from the ongoing Phase 2 trial suggest no treatment-related amyloid-related imaging abnormalities (ARIA) with PRI-002 Drug Safety and Monitoring Board recommended continued...

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's...

Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its...

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ...

SAN FRANCISCO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Over the past week, news stories on the “surprising” findings of the ACTIVE Study on dementia garnered headlines around the globe. The 20-year,...

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

20-year large NIH-funded study finds one type of cognitive training reduces incidence of diagnosed dementia - exercise available only in BrainHQ

Dr. Sanjeev Goel, M.D.'s 20-Year Mission: Racing Against Genetic Alzheimer's Risk to Find Answers for Millions